Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MAYNE PHARMA GROUP LIMITED Director's Dealing 2007

Dec 18, 2007

65396_rns_2007-12-18_a35d5b27-8fc7-444a-a244-07aa4b818105.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity HalcyGen Pharmaceuticals Limited
ABN 76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Bruce Mathieson
Date of last notice 14 December 2007

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct and Indirect interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
1) Mr Bruce Mathieson
2) Mrs Jill Mathieson
3) Investment Holdings Pty Ltd
4) BLM Superannuation Nominees Pty Ltd
Date of change 14, 17 & 19 December 2007
No. of securities held prior to change 250,000
Ordinary Fully Paid Shares (2)
1,912,345 Ordinary Fully Paid Shares (3)
1,090,000 Ordinary Fully Paid Shares (4)
250,000
Unlisted options for ordinary
shares @ 60 cents expiring 17
April 2011 (1)
Class Ordinary fully paid shares
Number acquired 135,000 (3)
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$60,324.11
  • See chapter 19 for defined terms.

11/3/2002

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change 250,000
Ordinary Fully Paid Shares (2)
2,047,345 Ordinary Fully Paid Shares (3)
1,090,000 Ordinary Fully Paid Shares (4)
250,000
Unlisted options for ordinary
shares @ 60 cents expiring 17
April 2011 (1)
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
On Market acquisition of ordinary shares

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [408 x 308] intentionally omitted <==

----- Start of picture text -----

Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
----- End of picture text -----

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002